Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Bluejay Diagnostics and SanyoSeiko deepen alliance to accelerate commercial launch of Symphony platform
Find out how Bluejay Diagnostics is accelerating Symphony’s commercial launch through an expanded SanyoSeiko partnership in manufacturing and supply chain.
Lupin (NSE: LUPIN) goes big in the U.S.—$250m Coral Springs facility sparks investor buzz
Find out how Lupin’s $250 million Coral Springs manufacturing facility could redefine America’s respiratory drug security and boost U.S. pharma resilience.
Immutep (ASX: IMM) closing in on critical readout — biotech traders discuss risk vs reward heading into 2026
Immutep Limited surpasses 170 patients in its global Phase III NSCLC trial, setting up a 2026 futility readout that could redefine its immunotherapy pipeline.
Regeneron’s Libtayo wins FDA approval as first adjuvant immunotherapy for high-risk skin cancer patients
Find out how Regeneron’s Libtayo is redefining skin cancer care as the first FDA-approved adjuvant immunotherapy for high-risk CSCC patients
Can PYC Therapeutics (ASX: PYC) turn clean safety data into investor confidence as ADOA trial expands?
PYC Therapeutics advances its RNA-based ADOA drug PYC-001 into a global Phase 1/2 multi-dose trial after a successful safety review. Find out what it means for biotech investors and patients.
Biotech meets blockchain: AlphaTON to tokenize cancer drug rights ahead of 2026 trial
Find out how AlphaTON and Cyncado plan to merge blockchain and biotech through tokenized cancer drug rights before their 2026 clinical trial begins.
RNAZ stock surges as TransCode Therapeutics buys Polynoma and wins $25m CK Life Sciences funding for metastatic cancer pipeline
Find out how TransCode Therapeutics’ $25M CK Life Sciences funding and Polynoma buyout could redefine RNAZ’s role in cancer immunotherapy.
Why Indegene’s BioPharm acquisition could become the blueprint for AI-first commercialization models in pharma
Discover how Indegene’s $104 million acquisition of BioPharm is setting a new paradigm in AI-driven precision pharma marketing.
Johnson & Johnson (NYSE: JNJ) gains FDA approval to expand SIMPONI into pediatric ulcerative colitis
FDA approves SIMPONI (golimumab) for children ≥15 kg with ulcerative colitis, expanding Johnson & Johnson’s immunology portfolio. Learn what it means for patients.
Verrica’s SITC reveal: can VP-315’s immune activation data reshape the skin cancer treatment landscape
Find out how Verrica’s VP-315 immune activation data at SITC 2025 could redefine non-surgical skin cancer treatment options for dermatologic oncology.